drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (CAR-T)
drug_description
Allogeneic T cells from the patient's prior HSCT donor engineered to express an anti-CD7 chimeric antigen receptor; upon CD7 binding, initiates cytotoxic killing of CD7+ malignant T cells via TCR-like signaling, perforin/granzyme pathways, and cytokine release. Expected on-target depletion of normal CD7+ T cells and some NK cells, causing T-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells from the prior HSCT donor are engineered to express an anti‑CD7 chimeric antigen receptor. CAR engagement with CD7 on malignant T cells triggers TCR-like signaling that activates cytotoxic effector functions, leading to perforin/granzyme-mediated lysis and cytokine release. On‑target effects include depletion of normal CD7+ T cells (and some NK cells), causing T‑cell aplasia.
drug_name
Prior-HSCT donor-derived CD7 CAR T-cell
nct_id_drug_ref
NCT06316427